Glassman Daniel, Hignett Sue, Rehman Shazza, Linforth Richard, Salhab Mohamed
Breast Surgery Department, Bradford Teaching Hospital NHS Trust, Bradford, U.K.
Medical Oncology Department, Bradford Teaching Hospital NHS Trust, Bradford, U.K.
Anticancer Res. 2017 Oct;37(10):5329-5341. doi: 10.21873/anticanres.11959.
The benefits of five years of adjuvant endocrine therapy for oestrogen receptor (ER)-positive early breast cancer are well established. However, recent evidence suggests that extended endocrine treatment and ovarian suppression in selected groups of patients have significant advantages. In this article, we review the current evidence for adjuvant endocrine therapy in breast cancer with focus on extended adjuvant endocrine therapy and ovarian suppression, and also highlight the advantages and disadvantages of these therapeutic strategies. A literature search was performed through PubMed, Medline, and Cochrane using the following search terms: Endocrine therapy, Tamoxifen, Anastrazole, Ovarian Suppression, Exemestane, Letrozole and STS Inhibitors. All available evidence for adjuvant endocrine therapy was reviewed and summarised to assess the current guidance and the progress of the management of patients with ER-positive breast cancer. Extended endocrine therapy should be tailored according to patient needs dictated by their individual risk factors, molecular type of breast cancer, menopausal status, comorbidities, life style and risk of recurrence. Clinicians ought to discuss with patients the pros and cons of different adjuvant endocrine therapy approaches and highlight the potential side effects and toxicity.
五年辅助内分泌治疗对雌激素受体（ER）阳性早期乳腺癌的益处已得到充分证实。然而，最近的证据表明，在特定患者群体中延长内分泌治疗和卵巢抑制具有显著优势。在本文中，我们回顾了乳腺癌辅助内分泌治疗的当前证据，重点关注延长辅助内分泌治疗和卵巢抑制，并强调了这些治疗策略的优缺点。通过PubMed、Medline和Cochrane进行文献检索，使用以下检索词：内分泌治疗、他莫昔芬、阿那曲唑、卵巢抑制、依西美坦、来曲唑和甾体类芳香化酶抑制剂。对辅助内分泌治疗的所有现有证据进行了回顾和总结，以评估当前的指导意见以及ER阳性乳腺癌患者管理的进展。延长内分泌治疗应根据患者个体风险因素、乳腺癌分子类型、绝经状态、合并症、生活方式和复发风险所决定的患者需求进行调整。临床医生应与患者讨论不同辅助内分泌治疗方法的利弊，并强调潜在的副作用和毒性。
